Heron Sells Substantially All Assets to CorMedix for $145M Cash Plus 14.58M Shares
HRTX sits 47% above its 52-week low of $0.261.
Summary
Heron agreed to sell substantially all of its assets to CorMedix for $145 million in cash plus 14,583,333 CorMedix shares, up to $55 million in ZYNRELEF earn-outs and a 5% royalty, ending its run as an operating biotech while keeping its NOLs and CorMedix stock.
Key Events · M&A and Partnerships · HRTX
-
CorMedix to Buy Heron's Assets
Definitive asset purchase agreement signed November 8, 2026: $145.0 million cash (subject to working capital and closing cash adjustments, with $2.0 million held in escrow) plus 14,583,333 CorMedix shares for substantially all of Heron's assets.
-
Contingent Consideration Adds Upside
Up to $55 million of earn-outs if ZYNRELEF 2028 net sales reach $65 million ($25 million) and $95 million (additional $30 million), plus a 5.0% royalty on CYNVANTI, SUSTOL and DLA-product net sales above $25 million in each of 2027, 2028 and 2029.
-
Heron Keeps NOLs and Stays Public
Heron retains approximately $2.3 billion of federal and state net operating losses as of September 30, 2026, the CorMedix shares, royalty and earn-out rights and cash; it does not intend to liquidate and will remain a Nasdaq-listed company.
-
Closing Needs Vote and HSR
Closing is targeted for the first quarter of 2027 and requires a majority of Heron shares outstanding, expiration of the HSR waiting period and Nasdaq listing approval of the CorMedix shares; a $4.0 million termination fee and up to $2.5 million expense reimbursement apply in specified cases.
Analysis · HRTX · Life Sciences
This is the end of Heron as an operating biotech. After a strategic alternatives review disclosed in August, the board signed a definitive deal to hand ZYNRELEF, APONVIE, CINVANTI and SUSTOL to CorMedix for $145 million in cash plus 14,583,333 CorMedix shares, with up to $55 million of ZYNRELEF earn-outs and a 5% royalty layered on top. What shareholders actually own after closing is a pile of CorMedix stock, cash, royalties and roughly $2.3 billion of net operating losses — not a commercial drug business. The cash portion alone is multiples of Heron's current market value, so the stock should reprice toward the deal math rather than trade on product trends. The remaining risk is execution: a Heron stockholder vote, HSR clearance, and a first-quarter 2027 target close, with a $4.0 million break fee if the board switches to a superior proposal.
At the time of this filing, HRTX was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $0.26 to $1.58. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.